Salta al contenuto
Universidad del Mar SIBUMAR Descubridor Institucional UMAR
  • Inicio
  • Búsqueda avanzada
  • Explorar
  • Entra
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
Avanzata
  • Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
Copertina

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Hepatology Research
Accesso online:
Acceder al recurso
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
  • Citazione
  • Invia SMS
  • Invia email
  • Stampa
  • Esporta il record
    • Esporta a RefWorks
    • Esporta a EndNoteWeb
    • Esporta a EndNote
  • Aggiungi alla lista
  • PLink permanente
  • Posseduto
  • Descrizione
  • Commenti
  • Documenti analoghi
  • MARC21
Descrizione
DOI:10.1111/hepr.70011

Documenti analoghi

  • Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
    di: Tomomitsu Matono, et al.
    Pubblicazione: (2025)
  • Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
    di: Tomomitsu Matono, et al.
    Pubblicazione: (2026)
  • Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
    di: Takeshi Hatanaka, et al.
    Pubblicazione: (2025)
  • Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
    di: Hideko Ohama, et al.
    Pubblicazione: (2026)
  • Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
    di: Kazuhiro Nouso, et al.
    Pubblicazione: (2026)
Universidad del Mar
Universidad del MarSistema Bibliotecario de la Universidad del MarDescubridor Institucional UMARImplementación y desarrollo: Mtro. Carlos Alonso Albores Pérez
InicioBúsqueda avanzadaExplorar
Visitas al Descubridor: 387,319© 2026 Universidad del Mar